This is the fifth post in a series on the TransCelerate Shared Investigator Platform (SIP). For more background, including benefits and challenges, see the previous posts.
For those of you who have not yet joined TransCelerate, or who have joined but have not yet adopted the SIP, here are some ideas to consider in your decision-making process:
Before you do anything else, ask your site users for feedback. What do they think and how do they feel about working on your studies? What are their biggest complaints? Would those complaints be addressed by adopting the SIP? Could those complaints be addressed in other ways that would be equally effective?
What is your long-term vision for how clinical trials work for your company? Are you working toward a future in which data collection and information sharing happens independently of IT systems, like leveraging the Internet of Things (IoT), blockchain technology, artificial intelligence, and/or possibilities that have yet to materialize? If your long-term vision is not yet clear, or if it involves minimal data entry (i.e., heavy reliance on automated data tracking), investing in the SIP might not be worthwhile for your organization at this time.
If the SIP really does seem like it would benefit your organization and your site users, do you realistically have the resources – time, money, human capital, expertise – to address all of the associated challenges? If not, what CAN you realistically do that would have the biggest positive impact on your site users and your business operations?
In our next post, we’ll offer guidance to those of you who are already members of TransCelerate and early adopters of the SIP. In the meantime, check out this brief video that describes a project we completed for one of the TransCelerate member companies, and fill out the form below to download our related guide, Perspectives on the TransCelerate Shared Investigator Platform.